Evaluating the Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer-Is Not Worse Good Enough?

JAMA Oncol. 2021 Jan 1;7(1):30-31. doi: 10.1001/jamaoncol.2020.5460.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Neoplastic Cells, Circulating* / pathology
  • Prognosis
  • Receptor, ErbB-2

Substances

  • Receptor, ErbB-2